JB Chemicals and Pharmaceuticals yesterday announced that it will acquire brands for the India market from Sanzyme, a player in the probiotics and reproductive health segment in the country. The transaction is valued at approximately Rs 628 crores, and is expected to be completed in the next two weeks subject to customary closing formalities, JB Chemicals informed via a statement.
The statement also noted that the acquired brands have a pan-India presence and wide distribution reach of ~ 300,000 chemists and ~100,000 prescribers. Probiotics portfolio includes Sporlac (which is the third-largest probiotics brand in India) and specialised products such as Lobun ( a probiotic used for delaying progression of Chronic Kidney Disease) and Oxalo (alternate risk-free therapy to decalcify kidney stones). The reproductive health segment has a complete range of infertility and hormone products. Following the acquisition, these products will derive significant visibility by leveraging JB Chemicals’ distribution network across the country.
Regarding Sanzyme, the statement mentioned that it is engaged in the manufacturing, distribution and marketing of speciality probiotics formulations, infertility management products and nutraceutical products. It operates in the gastroenterology, nephrology, urology and gyneacology therapy areas with brands such as Sporlac, Lobun and Gynogen. As per IQVIA MAT December 21 data, the revenue for the combined brands was Rs 160 crores.